Inherited genotype and prostate cancer outcomes

Cancer Epidemiology Biomarkers and Prevention

Volumn 11, Issue 10 I, 2002, Pages 945-952

  Rebbeck, Timothy R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450C17; FINASTERIDE; SEX HORMONE; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER GROWTH; CANCER INCIDENCE; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INHERITANCE; MALE; NORTH AMERICA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SCREENING TEST;

GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MASS SCREENING; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0036799275     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Stanford, J. L., Stephenson, R. A., Coyle, L. M., Cerhan, J., Correa, R., Eley, J. W., Gilliland, F., Hankey, B., Kolonel, L. N., Kosary, C., Ross, R., Severson, R., and West, D. Prostate Cancer Trends 1973-1995, SEER Program, National Cancer Institute. NIH Pub. No. 99-4543. Bethesda, MD, 1999.
2. Baron, E., and Angrist, A. Incidence of occult adenocarcinoma of the prostate after 50 years of age. Arch. Pathol., 32: 787-793, 1941.
3. Edwards, C., Steinthorsson, N., and Nicholson, D. An autopsy study of latent prostatic cancer. Cancer (Phila.), 6: 531-554, 1953.
4. Franks, L. M. Latent carcinoma of the prostate. J. Pathol. Bacteriol., 68: 603-616, 1954.
5. Halpert, B., and Schmalhorst, W. R. Carcinoma of the prostate in patients 70 to 79 years old. Cancer (Phila.), 19: 695-698, 1966.
6. Lundberg, S., and Berge, T. Prostatic carcinoma. An autopsy study. Scand. J. Urol. Nephrol., 4: 93-97, 1970.
7. Sakr, W. A., Haas, G. P., Cassin, B. F., Pontes, J. E., and Crissman, J. D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol., 150 (2 Pt. 1): 379-385, 1993.
8. Mettlin, C. Early detection of prostate cancer following repeated examinations by multiple modalities: results of the American Cancer Society National Prostate Cancer Detection Project. Clin. Investig. Med., 16: 440-447, 1993.
9. Ohori, M., Wheeler, T. M., Dunn, J. K., Stamey, T. A., and Scardino, P. T. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J. Urol., 152 (5 Pt. 2): 1714-1720, 1994.
10. Epstein, J. I., Walsh, P. C., Carmichael, M., and Brendler, C. B. Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. J. Am. Med. Assoc., 271: 368-374, 1994.
11. Hoff, B., and Pow-Sang, J. M. Observation in the management of localized prostate cancer. Cancer Control, 8: 151-154, 2001.
12. Kupelian, P. A., Katcher, J., Levin, H. S., and Klein, E. A. State T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys., 37: 1043-1052, 1997.
13. Zelefsky, M. J., Leibel, S. A., Gaudin, P. B., Kutcher, G. J., Fleshner, N. E., Venkatramen, E. S., Reuter, V. E., Fair, W. R., Ling, C. C., and Fuks, Z. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 41: 491-500, 1998.
14. Walsh, P. C. Radical prostatectomy. In: L. Dennis (ed.), Prostate Cancer, p. 52. New York: Springer Verlag, 2000.
15. Latil, A., and Lidereau, R. Genetic aspects of prostate cancer. Virchows Arch., 432: 389-406, 1998.
16. Ozen, M., and Pathak, S. Genetic alterations in human prostate cancer: a review of current literature. Anticancer Res., 20 (3B): 1905-1912, 2000.
17. Morganti, G., Gianferrari, L., Cresseri, A. Recherches clinicostatistiques et genetiques sur les neoplasias de la prostate. Acta Genet. Med. Gemellol., 6: 304-305, 1956.
18. Carter, B. S., Beaty, T. H., Steinberg, G. D., Childs, B., and Walsh, P. C. Mendelian inheritance of familial prostate cancer. Proc. Natl. Acad. Sci. USA, 89: 3367-3371, 1992.
19. Gronberg, H., Damber, L., Tavelin, B., and Damber, J. E. No difference in survival between sporadic, familial and hereditary prostate cancer. Br J. Urol., 82: 564-567, 1998.
20. Schaid, D. J., McDonnell, S. K., Blute, M. L., and Thibodeau, S. N. Evidence for autosomal dominant inheritance of prostate cancer. Am. J. Hum. Genet., 62: 1425-1438, 1998.
21. Ostrander, E. A., and Stanford, J. L. Genetics of prostate cancer: too many loci, too few genes. Am. J. Hum. Genet., 67: 1367-1375, 2000.
22. Carpten, J., Nupponen, N., Isaacs, S., Sood, R., Robbins, C., Xu, J., Faruque, M., Moses, T., Ewing, C., Gillanders, E., Hu, P., Bujnovszky, P., Makalowska, I., Baffoe-Bonnie, A., Faith, D., Smith, J., Stephan, D., Wiley, K., Brownstein, M., Gildea, D., Kelly, B., Jenkins, R., Hostetter, G., Matikainen, M., Schleutker, J., Klinger, K., Connors, T., Xiang, Y., Wang, Z., De Marzo, A., Papadopoulos, N., Kallioniemi, O, P., Burk, R., Meyers, D., Gronberg, H., Meltzer, P., Silverman, R., Bailey-Wilson, J., Walsh, P., Isaacs, W., and Trent, J. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat. Genet., 30: 181-184, 2002.
23. Tavtigian, S. V., Simard, J., Teng, D. H., Abtin, V., Baumgard, M., Beck, A., Camp, N. J., Carillo, A. R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J. M., Frank, D., Frye, C., Ghaffari, S., Gupte, J. S., Hu, R., Iliev, D., Janecki, T., Kort, E. N., Laity, K. E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B., Peterson, K. T., Reid, J. E., Richards, S., Schroeder, M., Smith, R., Snyder, S. C., Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A. M., Labrie, F., Skolnick, M. H., Neuhausen, S., Rommens, J., and Cannon-Albright, L. A. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet., 27: 172-180, 2001.
24. Rokman, A., Ikonen, T., Mononen, N., Autio, V., Matikainen, M. P., Koivisto, P. A., Tammela, T. L., Kallioniemi, O. P., and Schleutker, J. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res., 61: 6038-6041, 2001.
25. Suarez, B. K., Gerhard, D. S., Lin, J., Haberer, B., Nguyen, L., Kesterson, N. K., and Catalona, W. J. Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res., 61: 4982-4984, 2001.
26. Wang, L., McDonnell, S. K., Elkins, D. A., Slager, S. L., Christensen, E., Marks, A. F., Cunningham, J. M., Peterson, B. J., Jacobsen, S. J., Cerhan, J. R., Blute, M. L., Schaid, D. J., and Thibodeau, S. N. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res., 61: 6494-6499, 2001.
27. Xu, J., Zheng, S. L., Carpten, J. D., Nupponen, N. N., Robbins, C. M., Mestre, J., Moses, T. Y., Faith, D. A., Kelly, B. D., Isaacs, S. D., Wiley, K. E., Ewing, C. M., Bujnovszky, P., Chang, B., Bailey-Wilson, J., Bleecker, E. R., Walsh, P. C., Trent, J. M., Meyers, D. A., and Isaacs, W. B. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am. J. Hum. Genet., 68: 901-911, 2001.
28. Smith, J. R., Freije, D., Carpten, J. D., Gronberg, H., Xu, J., Isaacs, S. D., Brownstein, M. J., Bova, G. S., Guo, H., Bujnovszky, P., Nusskern, D. R., Damber, J. E., et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (Wash. DC), 274: 1371-1374, 1996.
29. Rodriguez, C., Calle, E. E., Miracle-McMahill, H. L., Tatham, L. M., Wingo, P. A., Thun, M. J., and Heath, C. W., Jr. Family history and risk of fatal prostate cancer. Epidemiology, 8: 653-657, 1997.
30. Keetch, D. W., Humphrey, P. A., Smith, D. S., Stahl, D., and Catalona, W. J. Clinical and pathological features of hereditary prostate cancer. J. Urol., 155: 1841-1843, 1996.
31. Carter, B. S., Bova, G. S., Beaty, T. H., Steinberg, G. D., Childs, B., Isaacs, W. B., and Walsh, P. C. Hereditary prostate cancer: epidemiologic and clinical features. J. Urol., 150: 797-802, 1993.
32. Bastacky, S. I., Wojno, K. J., Walsh, P. C., Carmichael, M. J., and Epstein, J. I. Pathological features of hereditary prostate cancer. J. Urol., 153 (3 Pt. 2): 987-992, 1995.
33. Bova, G. S., Partin, A. W., Isaacs, S. D., Carter, B. S., Beaty, T. L., Isaacs, W. B., and Walsh, P. C. Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J. Urol., 160 (3 Pt. 1): 660-663, 1998.
34. Valeri, A., Azzouzi, R., Drelon, E., Delannoy, A., Mangin, P., Fournier, G., Berthon, P., and Cussenot, O. Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. Prostate, 45: 66-71, 2000.
35. Gronberg, H., Isaacs, S. D., Smith, J. R., Carpten, J. D., Bova, G. S., Freije, D., Xu, J., Meyers, D. A., Collins, F. S., Trent, J. M., Walsh, P. C., and Isaacs, W. B. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. J. Am. Med. Assoc., 278: 1251-1255, 1997.
36. Goddard, K. A., Witte, J. S., Suarez, B. K., Catalona, W. J., and Olson, J. M. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes I and 4. Am. J. Hum. Genet. 68: 1197-1206, 2001.
37. Witte, J. S., Goddard, K. A., Conti, D. V., Elston, R. C., Lin, J., Suarez, B. K., Broman, K. W., Burmester, J. K., Weber, J. L., and Catalona, W. J. Genomewide scan for prostate cancer-aggressiveness loci. Am. J. Hum. Genet., 67: 92-99, 2000.
38. Rebbeck, T. R. Molecular epidemiology of prostate cancer. In: W. F. Greenlee, L. Samson, and J. P. Vanden Heuvel (eds.), Cellular and Molecular Toxicology, pp. 267-281. New York: Elsevier Press, 2001.
39. Rebbeck, T. R., Walker, A. H., Zeigler-Johnson, C., Weisburg, S., Martin, A. M., Nathanson, K. L., Wein, A. J., and Malkowicz, S. B. Association of HPC2/ELAC2 genotypes and prostate cancer. Am. J. Hum. Genet., 67: 1014-1019, 2000.
40. Vesprini, D., Nam, R. K., Trachtenberg, J., Jewett, M. A., Tavtigian, S. V., Emami, M., Ho, M., Toi, A., and Narod, S. A. HPC2 variants and screen-detected prostate cancer. Am. J. Hum. Genet., 68: 912-917, 2001.
41. Giovannucci, E., Stampfer, M. J., Krithivas, K., Brown, M., Dahl, D., Brufsky, A., Talcott, J., Hennekens, C. H., and Kantoff, P. W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA, 94: 3320-3323, 1997.
42. Ingles, S. A., Ross, R. K., Yu, M. C., Irvine, R. A., La Pera, G., Haile, R. W., and Coetzee, G. A. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst., 89: 166-170, 1997.
43. Stanford, J. L., Just, J. J., Gibbs, M., Wicklund, K. G., Neal, C. L., Blumenstein, B. A., and Ostrander, E. A. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res., 57: 1194-1198, 1997.
44. Platz, E. A., Giovannucci, E., Dahl, D. M., Krithivas, K., Hennekens, C. H., Brown, M., Stampfer, M. J., and Kantoff, P. W. The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol. Biomark. Prev., 7: 379-384, 1998.
45. Hsing, A. W., Gao, Y. T., Wu, G., Wang, X., Deng, J., Chen, Y. L., Sesterhenn, I. A., Mostofi, F. K., Benichou, J., and Chang, C. Polymorphic CAG and CGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res., 60: 5111-5116, 2000.
46. Edwards, S. M., Badzioch, M. D., Minter, R., Hamoudi, R., Collins, N., Ardern-Jones, A., Dowe, A., Osborne, S., Kelly, J., Shearer, R., Easton, D. F., Saunders, G. F., Dearnaley, D. P., and Eeles, R. A. Androgen receptor polymorphisms: association with prostate cancer risk, relapse, and overall survival. Int. J. Cancer, 84: 458-465, 1999.
47. Bratt, O., Borg, A., Kristoffersson, U., Lundgren, R., Zhang, Q. X., and Olsson, H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br. J. Cancer, 81: 672-676, 1999.
48. Makridakis, N. M., Ross, R. K., Pike, M. C., Crocitto, L. E., Kolonel, L. N., Pearce, C. L., Henderson, B. E., and Reichardt, J. K. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet, 354: 975-978, 1999.
49. Nam, R. K., Elhaji, Y., Krahn, M. D., Hakimi, J., Ho, M., Chu, W., Sweet, J., Trachtenberg, J., Jewett, M. A., and Narod, S. A. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J. Urol., 164: 567-572, 2001.
50. Febbo, P. G., Kantoff, P. W., Platz, E. A., Casey, D., Batter, S., Giovannucci, E., Hennekens, C. H., and Stampfer, M. J. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res., 59: 5878-5881, 1999.
51. Lunn, R. M., Bell, D. A., Mohler, J. L., and Taylor, J. A. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis (Lond.), 20: 1727-1731, 1999.
52. Wadelius, M., Andersson, A. O., Johansson, J. E., Wadelius, C., and Rane, E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics. 9: 635-639, 1999.
53. Gsur, A., Bernhofer, G, Hinteregger, S., Haidinger, G., Schatzl, G., Madersbacher, S., Marberger, M., Vutuc, C., and Micksche, M. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int. J. Cancer. 87: 434-437, 2000.
54. Habuchi, T., Liqing, Z., Suzuki, T., Sasaki, R., Tsuchiya, N., Tachiki, H., Shimoda, N., Satoh, S., Sato, K., Kakehi, Y., Kamoto, T., Ogawa, O., and Kato, T. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res., 60: 5710-5713, 2000.
55. Ma, J., Stampfer, M. J., Gann, P. H., Hough, H. L., Giovannucci, E., Kelsey, K. T., Hennekens, C. H., and Hunter, D. J. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol. Biomark. Prev., 7: 385-390, 1998.
56. Blazer, D. G., III. Umbach, D. M., Bostick, R. M., and Taylor, J. A. Vitamin D receptor polymorphisms and prostate cancer. Mol. Carcinog., 27: 18-23, 2000.
57. Taylor, J. A., Hirvonen, A., Watson, M., Pittman, G., Mohler, J. L., and Bell, D. A. Association of prostate cancer with Vitamin D receptor gene polymorphism. Cancer Res., 15: 4108-4110, 1996.
58. Waxman, D. J., Attisano, P. F., Guengerich, P. F., and Lapenson, D. P. Human liver microsomal steroid metabolism: identification of the major microsomal steroid 6β-hydroxylase cytochrome P450 enzyme. Arch. Biochem. Biophys., 263: 242-436, 1988.
59. Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J., and Malkowicz, S. B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 90: 1225-1229, 1998.
60. Paris, P. L., Kupelian, P. A., Hall, J. M., Williams, T. L., Levin, H., Klein, E. A., Casey, G. and Witte, J. S. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomark. Prev., 8: 901-905, 1999.
61. Allen, N. E., Forrest, M. S., and Key, T. J. The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol. Biomark. Prev., 10: 185-189, 2001.
62. Haiman. C. A., Stampfer. M. J., Giovannucci, E., Ma. J., Decalo, N. E., Kantoff, P. W., and Hunter, D. J. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol. Biomark. Prev., 10: 743-748, 2001.
63. Kittles, R. A., Panguluri, R. K., Chen, W., Massac, A., Ahaghotu, C., Jackson, A., Ukoli, F., Adams-Campbell, L., Isaacs, W., and Dunston, G. M. Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol. Biomark Prev., 10: 943-947, 2001.
64. Bruchovsky, N., and Wilson, J. D. The conversion of testosterone to 5-androstan-17β-ol-3-one by rat prostate in vivo and in vitro. J. Biol. Chem., 243: 2012-2021, 1968.
65. Coffey, D. S. Androgen action and the sex accessory tissues. In: E. Knobil, J. J. Neill. and L. L. Ewing (eds.), The Physiology of Reproduction, pp. 1081-1118. New York: Raven Press. 1988.
66. Makridakis, N., Ross, R. K., Pike, M. C., Chang, L., Stanczyk, F. Z., Kolonel, L. N., Shi, C. Y., Yu, M. C., Henderson, B. E., and Reichardt, J. K. V. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res., 57: 1020-1022, 1997.
67. Jaffe, J. M., Walker, A. H., MacBride, S., Peschel, R., Tomaszewski, J., Van Arsdalen, K., Wein, A. J., Malkowicz, S. B., and Rebbeck, T. R. Association of SRD5A2 genotype and pathologic characteristics of prostate tumors. Cancer Res., 60: 1626-1630, 2000.
68. Mononen, N., Ikonen, T., Syrjakoski, K., Matikainen, M., Schleutker, J., Tammela, T. L., Koivisto, P. A., and Kallioniemi, O. P. A missense substitution A49T in the steroid 5α-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br. J. Cancer, 84: 1344-1347, 2001.
69. Nam, R. K., Toi, A., Vesprini, D., Ho, M., Chu, W., Harvie, S., Sweet, J., Trachtenberg, J., Jewett, M. A., and Narod, S. A. V89L polymorphism of type-2. 5α-reductase enzyme gene predicts prostate cancer presence and progression. Urology, 57: 199-204, 2001.
70. Xue, W., Irvine, R. A., Yu, M. C., Ross, R. K., Coetzee, G. A., and Ingles, S. A. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res., 60: 839-841, 2000.
71. McMenamin, M. E., Soung, P., Perera, S., Kaplan, I., Loda, M., and Sellers, W. R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res., 59: 4291-4296, 1999.
72. Nathanson, K. L., Omaruddin, R., Malkowicz, S. B., and Rebbeck, T. R. An intronic variant in PTEN is not associated with prostate cancer risk. Cancer Epidemiol. Biomark. Prev., 10: 277-278, 2001.
73. George, D. J., Shepard, T. F., Ma, J., Giovannucci, E., Kantoff, P. W., and Stampfer, M. J. PTEN polymorphism (IVS4) is not associated with risk of prostate cancer. Cancer Epidemiol. Biomark. Prev., 10: 411-412, 2001.
74. Gross, C., Peehl, D. M., and Feldman, D. Vitamin D and prostate cancer. In: D. Feldman, F. H. Glorieux, and J. W. Pike (eds.), Vitamin D, pp. 1125-1139. San Diego: Academic Press, 1997.
75. Miller, G. J. Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev., 17: 353-360, 1999.
76. nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur. J. Hum. Genet., 7: 357-362, 1999.
77. Krynetski, E. Y., and Evans, W. E. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology (Basel), 61: 136-146, 2000.
78. Iyer, L., and Ratain, M. J. Pharmacogenetics and cancer chemotherapy. Eur. J. Cancer, 34: 1493-1499, 1998.
79. Huskeym, S. W., Dean, D. C., Miller, R. R., Rasmusson, G. H., and Chiu, S. H. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab. Dispos., 23: 1126-1135, 1995